The shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) currently has mean rating of 2.00 while 1 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 1 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.
The company’s mean estimate for sales for the current quarter ending Jun 16 is 30.88M by 4 analysts. The means estimate of sales for the year ending Dec-16 is 131.85M by 4 analysts.
The mean price target for the shares of Spectrum Pharmaceuticals, Inc. (SPPI) is at 9.33 while the highest price target suggested by the analysts is 12.00 and low price target is 6.00. The mean price target is calculated keeping in view the consensus of 3 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Spectrum Pharmaceuticals, Inc. (SPPI) stands at -0.29 while the EPS for the current year is fixed at -1.05 by 4 analysts.
The next one year’s EPS estimate is set at -0.97 by 4 analysts while a year ago the analysts suggested the company’s EPS at -1.05.
In its latest quarter ended on 31st Marh 2016, Spectrum Pharmaceuticals, Inc. (SPPI) reported earnings of $-0.14. The posted earnings topped the analyst’s consensus by $0.18 with the surprise factor of 56.20%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
On May 5, 2016 Spectrum Pharmaceuticals, Inc. (SPPI) announced financial results for the three-month period ended March 31, 2016.
Three-Month Period Ended March 31, 2016 (All numbers are approximate)
Total product sales were $35.2 million in the first quarter of 2016. Total product sales decreased 8.3% from $38.4 million in the first quarter of 2015.
Product sales in the first quarter included: FUSILEV® (levoleucovorin) net sales of $15.2 million, FOLOTYN® (pralatrexate injection) net sales of $13.3 million, ZEVALIN®(ibritumomab tiuxetan) net sales of $2.8 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $0.9 million and BELEODAQ® (belinostat for injection) net sales of $3.0 million.
Spectrum recorded net loss of $9.3 million, or $(0.14) per basic and diluted share in the three-month period ended March 31, 2016, compared to net loss of $25.6 million, or $(0.39) per basic and diluted share in the comparable period in 2015. Total research and development expenses were $15.5 million in the quarter, as compared to $15.9 million in the same period in 2015. Selling, general and administrative expenses were $22.0 million in the quarter, compared to $23.3 million in the same period in 2015.